In addition, EZH2 also promotes the transition of TAMs to the M2 phenotype and inhibits the Th1-type chemokine C-X-C Motif Chemokine Ligand 9 (CXCL9) to reduce CD8+ T cell infiltration, thereby reducing the anti-tumor immune response. Here, EZH2 is linked to neoplasm.